| Literature DB >> 35566505 |
Wan-Lin Wu1, Shu-Wen Chang1,2,3.
Abstract
This study aimed to investigate the relationships between subjective symptoms, objective signs, and dermatochalasis severity in dry-eye patients and the effects of lid hygiene on dry-eye parameters. We retrospectively enrolled 2328 patients who underwent dry-eye examinations and classified them into four groups by dermatochalasis severity. The SPEED and OSDI questionnaires were used to evaluate subjective symptoms. LipiView® II interferometry was used to measure lipid-layer thickness (LLT) and blink/incomplete blink rates and perform meibography. A slit-lamp-aided standardized evaluator measured meibomian gland expressibility (MGE). A meiboscale was used to grade meibomian gland dropout. Fluorescein tear-film break-up time (FTBUT) and superficial punctate keratitis (SPK) were recorded. The Schirmer test II with anesthetics was used to evaluate aqueous tear secretion. The effects of lid hygiene were evaluated in 644 patients who underwent second comprehensive examinations. The median age of patients was 55.3 [46.0-66.0] years (76.0% female). Patients with more severe dermatochalasis were less symptomatic and had less MGE, higher meiboscale grades and average LLT. Dermatochalasis severity was significantly associated with MGE and meiboscale grade in the upper lid. There were no significant differences in the Schirmer test, FTBUT, and SPK among the severity groups. Females were older and had higher LLT and less severe dermatochalasis. Lid hygiene significantly decreased subjective symptoms, LLT, and Schirmer results, increased FTBUT, but did not change MGE or meiboscale grades. Dermatochalasis severity participated in the pathophysiology of dry eyes. Lid hygiene significantly improved subjective symptoms and reduced LLT, more significantly in patients with less severe dermatochalasis.Entities:
Keywords: age; dermatochalasis; dry-eye; expressible meibomian gland; meibomian gland dysfunction; meiboscale; tear-film lipid-layer
Year: 2022 PMID: 35566505 PMCID: PMC9100659 DOI: 10.3390/jcm11092379
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Representative external eye photograph of eyelid configuration.
Figure 2Representative meibography images of the four meiboscale grades.
Figure 3Representative external eye photographs of fluorescein stain.
Summary of patients’ demographic characteristics. (A) Summary of patient age. (B) Distribution of dermatochalasis in females and males.
| (A) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Age (Years) | ||||||||
| N | Median | Q1 | Q3 | Minimum | Maximum |
| ||
| DM-1 | 917 | 50.9 | 41.0 | 62.0 | 20.0 | 90.0 |
| |
| DM-2 | 880 | 53.9 | 44.0 | 64.8 | 20.0 | 90.0 | ||
| DM-3 | 304 | 63.5 | 57.0 | 70.0 | 29.0 | 93.0 | ||
| DM-4 | 227 | 66.8 | 61.0 | 74.0 | 36.0 | 91.0 | ||
| Total | 2328 | 55.3 | 46.0 | 66.0 | 20.0 | 93.0 | ||
|
| ||||||||
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
| |
| DM-1 | 712 | 40.3% | 205 | 36.7% | 917 | 39.4% |
| |
| DM-2 | 679 | 38.3% | 201 | 36.0% | 880 | 37.8% | ||
| DM-3 | 209 | 11.8% | 95 | 17.0% | 304 | 13.1% | ||
| DM-4 | 170 | 9.6% | 57 | 10.2% | 227 | 9.7% | ||
| Total | 1770 | 100.0% | 558 | 100.0% | 2328 | 100.0% | ||
N: number of patients in the indicated group; Q1: lower quartile; Q3: upper quartile; p: statistical significance using the Kruskal–Wallis test (A) or Pearson’s chi-square test (B).
Summary and correlation of subjective symptoms (A).Summary of subjective symptoms according to dermatochalasis severity. (B) Correlations among dermatochalasis severity, age, and subjective symptom parameters.
| (A) | ||||||
|---|---|---|---|---|---|---|
| DM-1 | DM-2 | DM-3 | DM-4 | Total |
| |
| N | 917 | 880 | 304 | 227 | 2328 | |
| SPEED | 12.0 [8.0–16.0] | 12.0 [8.0–16.0] | 11.0 [7.0–15.0] | 10.0 [6.0–15.0] | 12.0 [8.0–16.0] |
|
| Frequency (SPEED) | 5.0 [4.0–7.0] | 5.0 [4.0–7.0] | 5.0 [3.0–7.0] | 5.0 [3.0–7.0] | 5.0 [4.0–7.0] |
|
| Severity (SPEED) | 6.0 [4.0–9.0] | 6.0 [4.0–8.0] | 6.0 [3.0–8.0] | 5.0 [3.0–8.0] | 6.0 [4.0–8.0] |
|
| OSDI | 37.5 [25.0–54.9] | 37.0 [22.5–56.3] | 33.3 [20.6–54.8] | 36.8 [18.8–55.4] | 36.4 [22.7–55.6] |
|
| OSDI (A) | 8.0 [5.0–11.0] | 8.0 [5.0–12.0] | 8.0 [4.0–12.0] | 8.0 [4.0–12.0] | 8.0 [5.0–12.0] | 0.984 |
| OSDI (B) | 4.0 [2.0–8.0] | 4.0 [2.0–8.0] | 4.0 [2.0–7.0] | 4.0 [1.0–7.0] | 4.0 [2.0–8.0] |
|
| OSDI (C) | 3.0 [2.0–7.0] | 3.0 [1.0–6.0] | 3.0 [1.0–6.0] | 3.0 [0.0–5.0] | 3.0 [1.0–7.0] |
|
|
| ||||||
|
|
|
| ||||
|
|
|
|
|
|
| |
| Age | 0.351 |
| 1 | |||
| SPEED | −0.085 |
| −0.149 |
| 0.053 |
|
| Frequency (SPEED) | −0.076 |
| −0.133 |
| 0.064 |
|
| Severity (SPEED) | −0.085 |
| −0.147 |
| 0.041 |
|
| OSDI | −0.041 | 0.076 | 0.016 | 0.487 | 0.040 |
|
| OSDI (A) | −0.026 | 0.273 | 0.077 |
| 0.054 |
|
| OSDI (B) | −0.063 |
| −0.111 |
| 0.033 | 0.077 |
| OSDI (C) | −0.110 |
| −0.153 |
| −0.005 | 0.810 |
DM: dermatochalasis (grade); numbers in brackets represent the 1st and 3rd quartiles; r: correlation coefficient by Spearman’s test. p: statistical significance using the Kruskal–Wallis test (A) or Spearman’s test (B).
Summary and correlations of meibomian gland-associated parameters. (A)Summary of meibomian gland-associated parameters according to dermatochalasis severity. (B) Correlations between dermatochalasis severity and lipid-related parameters.
| (A) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| DM-1 | DM-2 | DM-3 | DM-4 | Total |
| ||||
| N | 917 | 880 | 304 | 227 | 2328 | ||||
| LLT (nm) | 66.5 [56.0–86.0] | 69.0 [58.0–88.0] | 76.0 [58.0–97.0] | 81.0 [63.0–110.0] | 69.0 [57.0–91.0] |
| |||
| MGE | 8.0 [5.0–11.0] | 8.0 [5.0–11.0] | 8.0 [5.0–10.0] | 7.0 [5.0–10.0] | 8.0 [5.0–10.0] |
| |||
| MGE (upper) | 5.0 [3.0–6.0] | 5.0 [3.0–6.0] | 4.0 [2.0–6.0] | 4.0 [2.0–6.0] | 5.0 [3.0–6.0] |
| |||
| MGE (lower) | 3.0 [2.0–5.0] | 3.0 [2.0–5.0] | 3.0 [2.0–5.0] | 3.0 [2.0–5.0] | 3.0 [2.0–5.0] | 0.657 | |||
| Meiboscale (grade) | 1.0 [1.0–1.5] | 1.0 [1.0–1.5] | 1.5 [1.0–2.0] | 1.5 [1.0–2.0] | 1.5 [1.0–2.0] |
| |||
| Meiboscale (upper) | 1.0 [1.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–2.0] | 2.0 [1.0–3.0] | 1.0 [1.0–2.0] |
| |||
| Meiboscale (lower) | 1.0 [1.0–1.0] | 1.0 [1.0–1.0] | 1.0 [1.0–2.0] | 1.0 [1.0–2.0] | 1.0 [1.0–1.0] |
| |||
|
| |||||||||
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| ||
| LLT | 0.122 |
| 0.178 |
| 0.043 |
| 1 | ||
| MGE | Total | −0.040 | 0.051 | −0.074 |
| −0.005 | 0.781 | 0.117 |
|
| upper | −0.064 |
| −0.052 * |
| −0.014 | 0.462 | 0.075 |
| |
| lower | 0.000 | 0.991 | −0.066 |
| 0.000 | 0.988 | 0.117 |
| |
| Meiboscale | Total | 0.096 |
| 0.278 |
| 0.040 |
| −0.01 | 0.626 |
| upper | 0.100 |
| 0.297 |
| 0.057 |
| 0.003 | 0.896 | |
| lower | 0.033 | 0.111 | 0.122 |
| 0.011 | 0.560 | −0.052 |
| |
DM: dermatochalasis; LLT: average lipid-layer thickness; MGE: number of expressible meibomian glands; numbers in brackets represent 1st and 3rd quartiles; r: Spearman’s correlation coefficient; p: statistical significance using the Kruskal–Wallis test (A) or Spearman’s test (B).
Distribution of LLT ≥ 100 nm among the dermatochalasis groups.
| LLT < 100 | LLT ≥ 100 | Total |
| ||
|---|---|---|---|---|---|
| DM-1 | N | 774 | 144 | 918 | <0.001 |
| % within DM-1 | 84.3% | 15.7% | 100.0% | ||
| DM-2 | N | 744 | 135 | 879 | |
| % within DM-2 | 84.6% | 15.4% | 100.0% | ||
| DM-3 | N | 235 | 69 | 304 | |
| % within DM-3 | 77.3% | 22.7% | 100.0% | ||
| DM-4 | N | 150 | 77 | 227 | |
| % within DM-4 | 66.1% | 33.9% | 100.0% | ||
| Total | N | 1903 | 425 | 2328 | |
| % within DM | 81.7% | 18.3% | 100.0% |
LLT: average lipid-layer thickness (nm); DM: dermatochalasis; N: number of patients in the indicated group; p: statistical significance using Pearson’s chi-square test.
Summary and correlation of tear-film, blink patterns, and corneal parameters (A). Summary of tear-film, blink patterns, and corneal parameters according to dermatochalasis severity (B) Correlations among dermatochalasis, age, blinks, and tear-film parameters.
| (A) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| DM-1 | DM-2 | DM-3 | DM-4 | Total |
| |||||
| N | 917 | 880 | 304 | 227 | 2328 | |||||
| PB | 3.0 [1.0–6.0] | 3.0 [1.0–7.0] | 3.0 [1.0–5.0] | 2.0 [1.0–5.0] | 3.0 [1.0–6.0] |
| ||||
| PB (%) | 62.5 [27.3–92.9] | 66.7 [33.3–90.0] | 63.6 [26.8–91.3] | 50.0 [20.0–84.2] | 62.5 [28.6–90.9] | 0.106 | ||||
| TB | 7.0 [4.0–11.0] | 7.0 [4.0–10.0] | 6.0 [3.0–8.0] | 6.0 [3.0–9.0] | 6.0 [4.0–10.0] |
| ||||
| Schirmer (mm) | 4.0 [2.0–7.0] | 4.0 [2.0–6.0] | 4.0 [2.0–7.0] | 4.0 [2.0–7.0] | 4.0 [2.0–7.0] | 0.776 | ||||
| TBUT (s) | 3.0 [2.0–3.0] | 3.0 [2.0–3.0] | 3.0 [2.0–3.0] | 2.5 [2.0–3.0] | 3.0 [2.0–3.0] | 0.284 | ||||
| SPK (grade) | 0.0 [0.0–0.0] | 0.0 [0.0–0.0] | 0.0 [0.0–0.0] | 0.0 [0.0–0.0] | 0.0 [0.0–0.0] | 0.417 | ||||
|
| ||||||||||
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
| |
| TB | −0.115 |
| −0.218 |
| −0.087 |
| −0.019 | 0.416 | 0.017 | 0.471 |
| PB | −0.085 |
| −0.194 |
| −0.054 |
| −0.044 | 0.059 | 0.040 | 0.091 |
| PB (%) | −0.011 | 0.628 | −0.076 |
| −0.015 | 0.438 | −0.030 | 0.213 | 0.026 | 0.270 |
| Schirmer (mm) | 0.008 | 0.743 | −0.065 |
| −0.017 | 0.362 | 1 | −0.073 |
| |
| FTBUT (s) | −0.027 | 0.251 | −0.094 |
| −0.020 | 0.290 | 0.151 |
| −0.151 |
|
| SPK (grade) | −0.005 | 0.828 | 0.038 | 0.100 | 0.022 | 0.257 | −0.073 | 0.002 | 1 | |
DM: dermatochalasis; MGE: number of expressible meibomian glands; PB: number of partial blinks; TB: total number of blinks; PB (%): partial blink rate; FTBUT: fluorescein tear-film break-up time; SPK: superficial punctate keratitis; numbers in brackets represent 1st and 3rd quartiles; r: Spearman’s correlation coefficient; p: statistical significance using the Kruskal–Wallis test (A) or Spearman’s test (B).
Distribution of high LLT in females and males.
| N (% within Group) | Female | Male | Total |
|
|---|---|---|---|---|
| LLT < 100 | 1410 (79.70%) | 493 (88.40%) | 1903 (81.70%) | <0.001 |
| LLT ≥ 100 | 360 (20.30%) | 65 (11.60%) | 425 (18.30%) | |
| Total | 1770 | 558 | 2328 |
N: case number of the indicated group; p: statistical significance by Chi–square test.
Summary of subjective and objective dry-eye parameters before and after lid hygiene. (A) Summary of subjective symptoms before and after lid hygiene. (B) Summary of objective signs before and after lid hygiene.
| (A) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM 1–4 (N = 644) | DM-1 (N = 223) | DM-2 (N = 279) | DM-3 (N = 95) | DM4 (N = 47) | ||||||||||||
| Median | IQR |
| Median | IQR |
| Median | IQR |
| Median | IQR |
| Median | IQR |
| ||
| SPEED (total) | Before | 12.0 | 8.0 |
| 12.0 | 8.0 |
| 12.0 | 8.0 |
| 11.80 | 7.0 |
| 12.0 | 7.00 |
|
| After | 8.0 | 7.0 | 9.0 | 8.0 | 8.0 | 6.0 | 9.0 | 7.0 | 9.0 | 8.00 | ||||||
| Frequency (SPEED) | Before | 5.0 | 3.0 |
| 6.0 | 4.0 |
| 6.0 | 3.0 |
| 5.57 | 3.0 |
| 6.0 | 4.00 |
|
| After | 4.0 | 3.0 | 4.0 | 4.0 | 4.0 | 2.0 | 4.0 | 3.0 | 4.0 | 3.00 | ||||||
| Severity (SPEED) | Before | 6.0 | 4.0 |
| 6.0 | 5.0 |
| 6.0 | 4.0 |
| 6.23 | 5.0 |
| 6.0 | 5.00 |
|
| After | 4.0 | 5.0 | 5.0 | 5.0 | 4.0 | 3.0 | 5.0 | 4.0 | 5.0 | 5.00 | ||||||
| OSDI | Before | 36.4 | 33.5 |
| 35.4 | 33.3 |
| 37.5 | 31.8 |
| 41.70 | 35.8 |
| 45.5 | 46.53 |
|
| After | 25.0 | 26.7 | 25.0 | 25.0 | 27.1 | 25.0 | 29.4 | 33.5 | 31.3 | 26.45 | ||||||
| OSDI (A) | Before | 7.0 | 6.0 |
| 8.0 | 6.0 |
| 8.0 | 6.0 |
| 8.54 | 8.0 |
| 10.0 | 9.00 |
|
| After | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 6.0 | 8.0 | 6.0 | 6.00 | ||||||
| OSDI (B) | Before | 4.0 | 5.8 |
| 4.0 | 4.0 |
| 4.0 | 5.0 |
| 5.38 | 6.0 |
| 4.0 | 7.00 | 0.139 |
| After | 3.0 | 4.0 | 3.0 | 4.0 | 3.0 | 4.0 | 3.0 | 5.0 | 4.0 | 6.00 | ||||||
| OSDI (C) | Before | 3.0 | 4.8 |
| 3.0 | 5.0 |
| 3.0 | 5.0 |
| 4.06 | 5.0 |
| 3.0 | 6.00 | 0.194 |
| After | 3.0 | 4.0 | 3.0 | 5.0 | 3.0 | 4.0 | 3.0 | 5.0 | 3.0 | 5.00 | ||||||
|
| ||||||||||||||||
|
|
|
|
|
| ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| LLT (nm) | Before | 63.0 | 35.0 |
| 64.0 | 32.0 |
| 67.0 | 37.0 |
| 69.0 | 38.0 | 0.159 | 73.0 | 53.0 | 0.105 |
| After | 63.0 | 29.0 | 62.0 | 27.3 | 65.0 | 28.0 | 68.0 | 34.0 | 61.5 | 32.0 | ||||||
| MGE | Before | 7.0 | 5.0 | 0.127 | 7.0 | 6.0 | 0.260 | 8.0 | 4.0 | 0.901 | 8.0 | 5.0 | 0.453 | 8.0 | 6.0 | 0.647 |
| After | 8.0 | 5.0 | 8.0 | 6.0 | 8.0 | 5.0 | 8.0 | 4.0 | 8.0 | 5.0 | ||||||
| Meiboscale(grade) | Before | 1.0 | 1.0 | 0.740 | 1.5 | 1.0 | 1.000 | 1.5 | 0.5 | 0.414 | 1.5 | 1.0 | 0.782 | 2.0 | 1.0 | 0.180 |
| After | 1.0 | 1.0 | 1.5 | 1.0 | 1.5 | 0.5 | 1.5 | 1.0 | 1.5 | 1.0 | ||||||
| PB | Before | 3.0 | 5.0 |
| 3.0 | 5.0 |
| 4.0 | 6.0 |
| 3.0 | 5.0 |
| 2.0 | 5.0 | 0.355 |
| After | 2.0 | 4.0 | 2.0 | 4.0 | 2.0 | 4.0 | 2.0 | 4.0 | 2.0 | 5.3 | ||||||
| PB (%) | Before | 64.3 | 67.9 |
| 50.0 | 65.9 |
| 66.7 | 59.0 |
| 71.4 | 70.8 |
| 50.0 | 76.8 | 0.128 |
| After | 40.0 | 65.0 | 40.0 | 65.0 | 40.0 | 68.6 | 40.0 | 75.8 | 33.3 | 67.1 | ||||||
| TB | Before | 7.0 | 7.0 | 0.627 | 7.0 | 8.0 | 0.532 | 7.0 | 7.0 | 0.754 | 6.0 | 6.0 | 1.000 | 6.0 | 4.0 | 0.435 |
| After | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 6.0 | 7.0 | 8.0 | 7.0 | 6.3 | ||||||
| Schirmer test (mm) | Before | 4.0 | 5.0 |
| 4.0 | 6.0 |
| 4.0 | 5.0 |
| 4.0 | 5.0 | 0.138 | 4.0 | 5.0 | 0.262 |
| After | 4.0 | 4.0 | 3.0 | 5.0 | 3.0 | 4.3 | 4.0 | 4.0 | 4.0 | 6.0 | ||||||
| FTBUT (sec) | Before | 3.0 | 1.0 |
| 3.0 | 1.0 | 0.152 | 3.0 | 1.0 | 0.204 | 3.0 | 1.0 | 0.072 | 2.0 | 1.0 | 0.405 |
| After | 3.0 | 1.0 | 3.0 | 2.0 | 3.0 | 2.0 | 3.0 | 1.0 | 3.0 | 1.0 | ||||||
| SPK (grade) | Before | 0.0 | 0.0 | 0.103 | 0.0 | 0.0 | 0.206 | 0.0 | 0.0 | 0.895 | 0.0 | 0.0 | 0.197 | 0.0 | 0.0 | 0.102 |
| After | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||
DM: dermatochalasis; IQR: interquatile range; MGE: number of expressible meibomian glands; OSDI (A): subtotal of the frequency of symptoms; OSDI (B): subtotal of the frequency of activity limitation; OSDI (C): subtotal of the frequency of environmental factors triggering discomfort; LLT: average lipid-layer thickness; PB: number of partial blinks; B (%): partial blink rate; TB: total number of blinks; FTBUT: fluorescein tear-film break-up time; SPK: superficial punctate keratitis; p: statistical significance using the Friedman test.
Summary of subjective and objective dry-eye parameters in patients who did not perform lid hygiene. (A) Summary of subjective symptoms of 1st and 2nd examination. (B) Summary of objective signs of 1st and 2nd examination.
| (A) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM 1–4 (N = 238) | DM-1 (N =103) | DM-2 (N = 83) | DM-3 (N = 31) | DM-4 (N = 21) | ||||||||||||
| Exam | Median | IQR |
| Median | IQR |
| Median | IQR |
| Median | IQR |
| Median | IQR |
| |
| SPEED (total) | 1st | 11.0 | 8.0 | 0.087 | 12.0 | 8.0 | 0.179 | 11.0 | 7.0 | 0.265 | 10.0 | 7.0 | 0.883 | 10.0 | 8.0 | 0.458 |
| 2nd | 10.0 | 8.0 | 10.0 | 8.0 | 11.0 | 8.0 | 10.0 | 9.0 | 7.0 | 7.0 | ||||||
| Frequency (SPEED) | 1st | 5.0 | 3.0 | 0.062 | 5.0 | 3.0 | 0.312 | 5.0 | 3.0 | 0.154 | 4.0 | 3.0 | 0.726 | 5.0 | 3.0 | 0.308 |
| 2nd | 4.5 | 4.0 | 5.0 | 4.0 | 5.0 | 2.0 | 4.0 | 4.0 | 4.0 | 3.5 | ||||||
| Severity (SPEED) | 1st | 6.0 | 4.0 | 0.149 | 6.0 | 4.5 | 0.155 | 6.0 | 4.0 | 0.437 | 5.0 | 5.0 | 0.980 | 5.0 | 5.0 | 0.726 |
| 2nd | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 7.0 | 4.0 | 4.5 | ||||||
| OSDI(total) | 1st | 36.4 | 33.1 | 0.091 | 37.5 | 30.0 | 0.305 | 36.0 | 34.3 | 0.305 | 31.8 | 32.7 | 0.595 | 32.5 | 34.0 | 0.498 |
| 2nd | 31.3 | 31.5 | 31.3 | 38.9 | 31.8 | 27.5 | 32.5 | 22.2 | 29.2 | 24.9 | ||||||
| OSDI (A) | 1st | 8.0 | 6.3 | 0.093 | 8.0 | 6.5 | 0.180 | 8.0 | 8.0 | 0.506 | 7.0 | 7.0 | 0.498 | 7.0 | 8.0 | 0.539 |
| 2nd | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 6.0 | 5.0 | 5.0 | 8.0 | ||||||
| OSDI (B) | 1st | 4.0 | 5.0 |
| 4.0 | 6.0 |
| 4.0 | 5.0 |
| 3.0 | 4.0 | 0.070 | 3.0 | 5.0 | 0.378 |
| 2nd | 3.0 | 5.0 | 4.0 | 5.0 | 3.0 | 3.0 | 3.0 | 4.0 | 2.0 | 3.5 | ||||||
| OSDI (C) | 1st | 3.0 | 5.0 | 0.727 | 3.0 | 5.5 | 0.881 | 3.0 | 5.0 | 0.841 | 3.0 | 5.0 | 0.381 | 3.0 | 5.0 | 0.324 |
| 2nd | 3.0 | 4.3 | 3.0 | 4.0 | 3.0 | 5.0 | 3.0 | 7.0 | 3.0 | 2.5 | ||||||
|
| ||||||||||||||||
|
|
|
|
|
| ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| LLT (nm) | 1st | 69.0 | 33.0 | 0.368 | 66.0 | 28.0 | 0.797 | 69.0 | 29.0 | 0.244 | 77.0 | 38.0 | 0.748 | 86.0 | 48.0 | 0.370 |
| 2nd | 68.5 | 36.0 | 64.0 | 35.0 | 67.0 | 29.0 | 74.0 | 34.0 | 83.0 | 42.5 | ||||||
| MGE | 1st | 8.0 | 6.0 | 0.720 | 8.0 | 5.0 | 0.208 | 8.0 | 7.0 | 0.757 | 8.0 | 5.0 | 0.146 | 8.0 | 6.0 | 0.479 |
| 2nd | 8.0 | 6.0 | 8.0 | 6.0 | 8.0 | 6.0 | 8.0 | 6.0 | 5.0 | 6.0 | ||||||
| Meiboscale | 1st | 1.0 | 0.5 |
| 1.0 | 0.5 | 0.126 | 1.0 | 0.5 | 0.185 | 1.5 | 1.0 | 0.261 | 1.5 | 1.0 | 0.596 |
| 2nd | 1.5 | 1.0 | 1.5 | 1.0 | 1.5 | 1.0 | 1.5 | 1.5 | 1.5 | 1.0 | ||||||
| PB | 1st | 3.0 | 5.0 |
| 4.0 | 5.0 | 0.331 | 3.0 | 5.0 | 0.051 | 3.0 | 4.0 | 0.176 | 3.0 | 4.0 |
|
| 2nd | 2.0 | 4.0 | 3.0 | 5.0 | 2.0 | 3.0 | 2.0 | 3.0 | 1.0 | 3.0 | ||||||
| PB (%) | 1st | 62.5 | 60.8 |
| 62.5 | 61.6 |
| 60.0 | 62.6 |
| 63.1 | 58.5 | 0.890 | 50.0 | 60.1 | 0.110 |
| 2nd | 50.0 | 63.3 | 50.0 | 57.5 | 48.3 | 62.3 | 66.7 | 63.3 | 33.3 | 77.2 | ||||||
| TB | 1st | 6.0 | 6.0 | 0.901 | 7.0 | 7.0 | 0.389 | 6.0 | 6.0 | 0.905 | 6.0 | 5.0 | 0.459 | 6.0 | 6.0 | 0.506 |
| 2nd | 6.0 | 7.0 | 7.0 | 7.0 | 6.0 | 7.0 | 5.0 | 6.0 | 4.0 | 6.0 | ||||||
| Schirmer test (mm) | 1st | 4.0 | 5.0 |
| 4.0 | 5.0 |
| 4.0 | 5.0 | 0.296 | 4.0 | 4.0 | 0.651 | 4.0 | 5.0 |
|
| 2nd | 3.0 | 5.0 | 3.0 | 5.0 | 4.0 | 5.0 | 4.0 | 4.3 | 2.0 | 4.0 | ||||||
| FTBUT (sec) | 1st | 3.0 | 1.0 | 0.555 | 3.0 | 1.0 | 0.575 | 3.0 | 1.0 | 0.846 | 3.0 | 1.0 | 0.881 | 3.0 | 1.0 | 0.678 |
| 2nd | 3.0 | 1.0 | 3.0 | 2.0 | 3.0 | 1.0 | 3.0 | 1.0 | 2.0 | 1.0 | ||||||
| SPK (grade) | 1st | 0.0 | 0.0 | 0.187 | 0.0 | 0.0 |
| 0.0 | 0.0 | 0.815 | 0.0 | 1.0 | 0.647 | 0.0 | 0.0 | 0.672 |
| 2nd | 0.0 | 1.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||
DM: dermatochalasis; IQR: interquatile range; MGE: number of expressible meibomian glands; OSDI (A): subtotal of the frequency of symptoms; OSDI (B): subtotal of the frequency of activity limitation; OSDI (C): subtotal of the frequency of environmental factors triggering discomfort; LLT: average lipid-layer thickness; PB: number of partial blinks; B (%): partial blink rate; TB: total number of blinks; FTBUT: fluorescein tear-film break-up time; SPK: superficial punctate keratitis; p: statistical significance using the Friedman tes.